Stephen Baxter, an analyst from Wells Fargo, maintained the Buy rating on Universal Health (UHS – Research Report). The associated price target is $225.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Stephen Baxter has given his Buy rating due to a combination of factors that highlight Universal Health’s financial performance and strategic positioning. The company’s adjusted EBITDA showed a significant year-over-year increase, surpassing both Wells Fargo Securities and consensus estimates. This indicates strong operational efficiency and cost management, as evidenced by the improved EBITDA margin and reduced supply costs as a percentage of revenue.
Despite some challenges in same-store revenue growth, particularly in the behavioral segment, the overall revenue growth and strategic capital deployment, including share repurchases, reflect a positive outlook. The company’s balance sheet remains robust with a manageable level of net debt relative to its EBITDA, suggesting financial stability. These factors collectively support the Buy rating, as they indicate potential for future growth and shareholder value creation.
In another report released today, Barclays also maintained a Buy rating on the stock with a $257.00 price target.
UHS’s price has also changed moderately for the past six months – from $204.550 to $172.910, which is a -15.47% drop .